$SIBN
SI-BONE Inc Stock $sibn

$sibn Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000145983924000014 Filed on February 27, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$37.87M	$38.86M	$138.9M
YoY Change	15.77%	21.61%	30.52%
Cost Of Revenue	$8.002M	$10.18M	$29.47M
YoY Change	35.08%	100.1%	87.62%
Gross Profit	$29.87M	$28.68M	$109.4M
YoY Change	11.5%	6.75%	20.63%
Gross Profit Margin	78.87%	73.8%	78.78%
Selling, General & Admin	$37.56M	$37.02M	$141.3M
YoY Change	7.98%	6.75%	3.39%
% of Gross Profit	125.78%	129.1%	129.16%
Research & Development	$4.345M	$4.162M	$15.03M
YoY Change	32.03%	19.6%	10.28%
% of Gross Profit	14.55%	14.51%	13.73%
Depreciation & Amortization	$1.089M	$1.573M	$5.428M
YoY Change	0.28%	56.99%	57.24%
% of Gross Profit	3.65%	5.49%	4.96%
Operating Expenses	$41.91M	$41.18M	$156.4M
YoY Change	10.06%	7.92%	4.02%
Operating Profit	-$12.04M	-$12.51M	-$46.93M
YoY Change	6.64%	10.73%	-21.27%
Interest Expense	$881.0K	$1.338M	$3.462M
YoY Change	5.13%	135.56%	22.81%
% of Operating Profit
Other Income/Expense, Net	-$93.00K	$185.0K	$141.0K
YoY Change	-225.68%	-26.29%	-206.82%
Pretax Income	-$10.90M	-$10.98M	-$43.49M
YoY Change	-1.99%	-1.72%	-29.16%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$10.90M	-$10.98M	-$43.34M
YoY Change	-1.99%	-1.72%	-29.25%
Net Earnings / Revenue	-28.8%	-28.26%	-31.2%
Basic Earnings Per Share	-$0.27		-$1.13
Diluted Earnings Per Share	-$0.27	-$0.27	-$1.13
COMMON SHARES
Basic Shares Outstanding	41.06M shares	40.50M shares	38.43M shares
Diluted Shares Outstanding	40.93M shares		38.43M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$157.8M	$166.0M	$166.0M
YoY Change	83.59%	70.64%	70.64%
Cash & Equivalents	$32.04M	$33.27M	$33.27M
Short-Term Investments	$125.8M	$132.7M	$132.7M
Other Short-Term Assets	$2.647M	$3.173M	$3.173M
YoY Change	29.44%	34.16%	34.16%
Inventory	$21.05M	$20.25M	$20.25M
Prepaid Expenses
Receivables	$22.11M	$21.95M	$21.95M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$203.6M	$211.4M	$211.4M
YoY Change	58.59%	53.62%	53.62%
LONG-TERM ASSETS
Property, Plant & Equipment	$17.35M	$16.00M	$18.71M
YoY Change	4.32%	2.8%	-4.4%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$323.0K	$325.0K	$325.0K
YoY Change	-13.64%	-13.33%	-13.33%
Total Long-Term Assets	$20.09M	$19.03M	$19.03M
YoY Change	-2.85%	-4.56%	-4.56%
TOTAL ASSETS
Total Short-Term Assets	$203.6M	$211.4M	$211.4M
Total Long-Term Assets	$20.09M	$19.03M	$19.03M
Total Assets	$223.7M	$230.4M	$230.4M
YoY Change	50.07%	46.25%	46.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.661M	$4.588M	$4.588M
YoY Change	43.71%	-26.93%	-26.93%
Accrued Expenses	$11.77M	$17.45M	$18.87M
YoY Change	18.91%	29.17%	43.94%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$20.86M	$23.46M	$23.46M
YoY Change	25.46%	10.76%	10.76%
LONG-TERM LIABILITIES
Long-Term Debt	$36.11M	$36.07M	$36.07M
YoY Change	0.47%	2.54%	2.54%
Other Long-Term Liabilities	$16.00K	$18.00K	$1.529M
YoY Change	-38.46%	-40.0%	-47.29%
Total Long-Term Liabilities	$36.12M	$36.08M	$37.59M
YoY Change	0.44%	2.51%	-1.26%
TOTAL LIABILITIES
Total Short-Term Liabilities	$20.86M	$23.46M	$23.46M
Total Long-Term Liabilities	$36.12M	$36.08M	$37.59M
Total Liabilities	$58.18M	$61.05M	$61.05M
YoY Change	5.55%	3.04%	3.04%
SHAREHOLDERS EQUITY
Retained Earnings	-$411.3M	-$400.4M
YoY Change	11.71%	12.14%
Common Stock	$4.000K	$4.000K
YoY Change	33.33%	33.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$165.5M	$169.4M	$169.4M
YoY Change
Total Liabilities & Shareholders Equity	$223.7M	$230.4M	$230.4M
YoY Change	50.07%	46.25%	46.25%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$10.90M	-$10.98M	-$43.34M
YoY Change	-1.99%	-1.72%	-29.25%
Depreciation, Depletion And Amortization	$1.089M	$1.573M	$5.428M
YoY Change	0.28%	56.99%	57.24%
Cash From Operating Activities	-$7.571M	-$2.297M	-$18.71M
YoY Change	-29.59%	-66.1%	-55.08%
INVESTING ACTIVITIES
Capital Expenditures	$2.082M	$1.093M	$7.799M
YoY Change	-19.27%	-34.16%	-17.97%
Acquisitions
YoY Change
Other Investing Activities	$8.429M	-$17.82M	-$52.00M
YoY Change	-40.98%	-1118.81%	-877.03%
Cash From Investing Activities	$6.347M	-$18.91M	-$59.80M
YoY Change	-45.77%	-21349.44%	2024.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$83.67M
YoY Change
Debt Paid & Issued, Net	$0.00		$35.28M
YoY Change	-100.0%
Cash From Financing Activities	$105.0K	842.0K	$90.93M
YoY Change	-91.29%	21.5%	4038.96%
NET CHANGE
Cash From Operating Activities	-$7.571M	-2.297M	-$18.71M
Cash From Investing Activities	$6.347M	-18.91M	-$59.80M
Cash From Financing Activities	$105.0K	842.0K	$90.93M
Net Change In Cash	-$1.231M	-20.37M	$12.55M
YoY Change	-154.66%	239.85%	-129.4%
FREE CASH FLOW
Cash From Operating Activities	-$7.571M	-$2.297M	-$18.71M
Capital Expenditures	$2.082M	$1.093M	$7.799M
Free Cash Flow	-$9.653M	-$3.390M	-$26.51M
YoY Change	-27.6%	-59.81%	-48.18%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	8002000	usd
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4106213	shares
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001459839
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrent
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-38701
CY2023	dei	Entity Registrant Name EntityRegistrantName	SI-BONE, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-2216351
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	471 El Camino Real
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 101
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Santa Clara
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	95050
CY2023	dei	City Area Code CityAreaCode	408
CY2023	dei	Local Phone Number LocalPhoneNumber	207-0700
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2023	dei	Trading Symbol TradingSymbol	SIBN
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	1100000000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	41064511	shares
CY2023	dei	Auditor Firm AuditorFirmId	238
CY2023	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2023	dei	Auditor Location AuditorLocation	San Jose, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33271000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20717000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	132748000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	76573000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1118000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	400000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	21953000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	20674000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	20249000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	17282000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3173000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2365000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	211394000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	137611000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	16000000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15564000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2706000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4002000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	325000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	375000	usd
CY2023Q4	us-gaap	Assets Assets	230425000	usd
CY2022Q4	us-gaap	Assets Assets	157552000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4588000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6279000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17452000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13511000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1416000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1388000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	23456000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	21178000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	36065000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	35171000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1511000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2871000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	18000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	30000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	61050000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	59250000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40693299	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40693299	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34731577	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34731577	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	3000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	569477000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	455172000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	335000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	232000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-400441000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-357105000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	169375000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	98302000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	230425000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	157552000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	138886000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	106409000	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	29466000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	15705000	usd
CY2023	us-gaap	Gross Profit GrossProfit	109420000	usd
CY2022	us-gaap	Gross Profit GrossProfit	90704000	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	107726000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	31069000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	156351000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	150313000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-46931000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-59609000	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	6916000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	1304000	usd
CY2023	us-gaap	Interest Expense InterestExpense	3462000	usd
CY2022	us-gaap	Interest Expense InterestExpense	2819000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	141000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-132000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-43336000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-61256000	usd
CY2023	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	166000	usd
CY2022	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-65000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-63000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-55000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-43233000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-61376000	usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.13
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.13
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.79
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.79
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38427419	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38427419	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34201824	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34201824	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	134420000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	379000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1818000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	23061000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-55000	usd
CY2022	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-65000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-61256000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	98302000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	83672000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4386000	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2191000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	24057000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-63000	usd
CY2023	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	166000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-43336000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	169375000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-43336000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-61256000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	24057000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	23061000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5428000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3452000	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	761000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	150000	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	1709000	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	319000	usd
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	4009000	usd
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-229000	usd
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	208000	usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	198000	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-1302000	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-153000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2122000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6479000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4719000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6028000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	762000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-810000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1118000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2529000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3888000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1207000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18713000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-41655000	usd
CY2023	sibn	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	137500000	usd
CY2022	sibn	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	126200000	usd
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	189499000	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	119508000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7799000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9507000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-59798000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2815000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	83671000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2023	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	36000000	usd
CY2022	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
CY2023	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	35275000	usd
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	usd
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	40000	usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4386000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	379000	usd
CY2023	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	2191000	usd
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1818000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	90933000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2197000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	132000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-429000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	12554000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-42702000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20717000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	63419000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33271000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20717000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	3263000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	2621000	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	501000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1115000	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	The Company and Nature of Business<div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SI-BONE, Inc. (the “Company”) was incorporated in the state of Delaware on March 18, 2008 and is headquartered in Santa Clara, California. The Company is a medical device company that has pioneered a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint for treatment of musculoskeletal disorders of the sacropelvic anatomy. The Company introduced its first generation iFuse implant in 2009 in the United States, in 2010 in certain countries in the European Union, and in 2015 in certain countries in the rest of the world. The second generation iFuse implant, iFuse 3-D, was introduced in 2017 followed by iFuse-TORQ in 2021 and iFuse Bedrock Granite in 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2023, the Company received a total of $83.7 million of net proceeds after deducting the underwriting discounts and commissions from the offering of 3,775,000 shares of the Company’s common stock and the exercise of underwriter's option to purchase from the Company an additional 566,250 shares of the Company's common stock, at a public offering price of $22.00 per share. Of these shares, 272,753 shares were offered by a selling stockholder, and the Company did not receive any proceeds from the sale by the selling stockholder.</span></div><div style="margin-bottom:12pt;margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is subject to uncertainties related to liquidity, the ability to meet covenants and access to funding for its capital needs as the financial service industry has experienced disruptions characterized by the bankruptcy, failure, collapse or sale of various financial institutions. The Company’s cash and cash equivalents are primarily invested in deposits and money market accounts with two major financial institutions in the U.S. Deposits in these banks may exceed the federally insured limits or any other insurance provided on such deposits, if any. The Company had accounts with Silicon Valley Bank (“SVB”). On March 10, 2023, California regulators shut down SVB and the FDIC was appointed as SVB’s receiver. On March 26, 2023, the FDIC announced that it had entered into a purchase and assumption agreement with First-Citizens Bank & Trust Company (“First-Citizens”) under which all deposits of the former Silicon Valley Bank were assumed by First-Citizens.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">First-Citizens acquired the rights as lender under the Company’s Loan and Security Agreement as amended. To date, the Company has not experienced any losses on its deposits of cash, cash equivalents and marketable securities and continues to have access to these funds. As such the Company's future results of operations and liquidity could be adversely impacted by a variety of factors including those discussed in the section entitled "Risk Factors" in this report. As of the date of issuance of these consolidated financial statements, the extent to which the current macroeconomic environment may materially impact the Company's financial condition, liquidity, or results of operations remains uncertain.</span></div>
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:9pt;padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Significant accounting estimates and management judgments reflected in the consolidated financial </span>statements primarily includes the fair value of performance-based restricted stock unit awards. Estimates are based on historical experience, where applicable and other assumptions believed to be reasonable by the management. Actual results could differ from those estimates.
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassification of prior year presentation</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications are limited to the consolidated statements of cash flows and have no effect on the reported results of operations.</span></div>
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	138886000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	106409000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and marketable securities. The Company’s cash and marketable securities are deposited with financial institutions in the United States and in Europe. The majority of the Company’s cash and marketable securities are deposited with a single financial institution in the United States Deposits in this institution exceed the amount of insurance provided on such deposits. The Company has not experienced any net losses on its deposits of cash and marketable securities.</span></div>
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	400000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	264000	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	761000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	150000	usd
CY2023	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	43000	usd
CY2022	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	14000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1118000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	400000	usd
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2023	sibn	Standard Product Warranty Term StandardProductWarrantyTerm	P1Y
CY2023	sibn	Sales Credit Reserve Period SalesCreditReservePeriod	P1Y
CY2023	us-gaap	Advertising Expense AdvertisingExpense	1100000	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	1600000	usd
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	23331000	usd
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	23331000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss	132683000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	67000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	132748000	usd
CY2023Q4	sibn	Marketable Securities Amortized Cost MarketableSecuritiesAmortizedCost	156014000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	67000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	156079000	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	8002000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	0	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	0	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	200000	usd
CY2022	us-gaap	Debt Securities Available For Sale Accrued Interest Writeoff DebtSecuritiesAvailableForSaleAccruedInterestWriteoff	0	usd
CY2023	us-gaap	Debt Securities Available For Sale Accrued Interest Writeoff DebtSecuritiesAvailableForSaleAccruedInterestWriteoff	0	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	18800000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1400000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	15600000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1700000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	31246000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	25771000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	15246000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10207000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	16000000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15564000	usd
CY2023	us-gaap	Depreciation Depreciation	5400000	usd
CY2022	us-gaap	Depreciation Depreciation	3400000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	0	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	0	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	13464000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11365000	usd
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1360000	usd
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	818000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	929000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	355000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1699000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	973000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17452000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13511000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	1552000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	1599000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	465000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	461000	usd
CY2023	us-gaap	Lease Cost LeaseCost	2017000	usd
CY2022	us-gaap	Lease Cost LeaseCost	2060000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	1632000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	1600000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	143000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	127000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y2M12D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y18D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0587
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0577
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1543000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1019000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	547000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	9000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3118000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	191000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2927000	usd
CY2023Q4	us-gaap	Purchase Obligation PurchaseObligation	400000	usd
CY2022Q4	us-gaap	Purchase Obligation PurchaseObligation	800000	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	36720000	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	35700000	usd
CY2023Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	81000	usd
CY2022Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	73000	usd
CY2023Q4	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	574000	usd
CY2022Q4	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	456000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	36065000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	35171000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	36065000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	35171000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	8400000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	14400000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	13920000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	0	usd
CY2023Q2	sibn	Stock Issued During Period Exercise Of Warrants Shares StockIssuedDuringPeriodExerciseOfWarrantsShares	22603	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	118122	shares
CY2023	sibn	Class Of Warrant Or Right Shares Issued ClassOfWarrantOrRightSharesIssued	0	shares
CY2023	sibn	Class Of Warrant Or Right Shares Exercised ClassOfWarrantOrRightSharesExercised	32983	shares
CY2023	sibn	Class Of Warrant Or Right Shares Expired ClassOfWarrantOrRightSharesExpired	0	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	85139	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40693299	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40693299	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34731577	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34731577	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2009513	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.73
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	80571	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.70
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	25601	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	15.05
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1903341	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.82
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	698627	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.28
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	16006	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	21.22
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1188708	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.14
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y6M3D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	13197000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1188708	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	10.14
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P3Y6M3D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	13197000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1188708	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	10.14
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P3Y6M3D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	13197000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	11700000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1000000	usd
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	1188708	shares
CY2023	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P3Y6M3D
CY2023Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	10.14
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1188708	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	10.14
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-43336000	usd
CY2023	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	178918	shares
CY2022	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	170717	shares
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2200000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1800000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	24057000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	23061000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-61256000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38427419	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38427419	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34201824	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34201824	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.13
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.13
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.79
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.79
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3660931	shares
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-43491000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-61396000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	155000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	140000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-43336000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-61256000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	10606000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	13085000	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	1856000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	2997000	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-28000	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-92000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	12434000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	15990000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	12434000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	15990000	usd
CY2023	sibn	Deferred Income Tax Expense Benefit Net Of Valuation Allowance DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance	0	usd
CY2022	sibn	Deferred Income Tax Expense Benefit Net Of Valuation Allowance DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance	0	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.043
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.049
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.013
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.007
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.287
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.261
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.028
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.003
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.021
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.001
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.028
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.001
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	85173000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	77057000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	5342000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	4464000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	3698000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	2616000	usd
CY2023Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	4378000	usd
CY2022Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	4447000	usd
CY2023Q4	sibn	Deferred Tax Assets Depreciation And Amortization DeferredTaxAssetsDepreciationAndAmortization	474000	usd
CY2022Q4	sibn	Deferred Tax Assets Depreciation And Amortization DeferredTaxAssetsDepreciationAndAmortization	263000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3474000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3378000	usd
CY2023Q4	sibn	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	735000	usd
CY2022Q4	sibn	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	1079000	usd
CY2023Q4	sibn	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	4614000	usd
CY2022Q4	sibn	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	2486000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	107888000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	95790000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	678000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1014000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	678000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1014000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	107210000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	94776000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	94776000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	78786000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	12434000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	15990000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	107210000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	94776000	usd
CY2023Q4	sibn	Operating Loss Carryforwards Limited OperatingLossCarryforwardsLimited	1400000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2944000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2655000	usd
CY2023	sibn	Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions	-726000	usd
CY2022	sibn	Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions	-12000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	411000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	301000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2629000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2944000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	0	usd
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001459839-24-000014-index-headers.html	Edgar Link	pending
0001459839-24-000014-index.html	Edgar Link	pending
0001459839-24-000014.txt	Edgar Link	pending
0001459839-24-000014-xbrl.zip	Edgar Link	pending
a2023-10x02recoupmentclawb.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
secondamendmenttocreditfac.htm	Edgar Link	pending
Show.js	Edgar Link	pending
si-bonermsmsa022324final.htm	Edgar Link	pending
sibn-20231231.htm	Edgar Link	pending
sibn-20231231.xsd	Edgar Link	pending
sibn-ex211_12312023listxof.htm	Edgar Link	pending
sibn-ex231_pwcxconsent1231.htm	Edgar Link	pending
sibn-ex311_12312310xk.htm	Edgar Link	pending
sibn-ex312_12312310xk.htm	Edgar Link	pending
sibn-ex321_12312310xk.htm	Edgar Link	pending
sibn-20231231_lab.xml	Edgar Link	unprocessable
sibn-20231231_pre.xml	Edgar Link	unprocessable
sibn-20231231_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
sibn-20231231_cal.xml	Edgar Link	unprocessable
sibn-20231231_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SIBN
SI-BONE Inc Stock $sibn

2024 Q1 Form 10-K Financial Statement

#000145983924000014 Filed on February 27, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SIBN SI-BONE Inc Stock $sibn

2024 Q1 Form 10-K Financial Statement

#000145983924000014 Filed on February 27, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SIBN
SI-BONE Inc Stock $sibn